Full case includes Shepard's, Headnotes, Legal Analytics from Lex Machina, and more.
931 F.3d 1342 *; 2019 U.S. App. LEXIS 22517 **; 2019 U.S.P.Q.2D (BNA) 281074; 2019 WL 3418549
CELGENE CORPORATION, Appellant v. LAURA A. PETER, DEPUTY UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND DEPUTY DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE, Intervenor
Subsequent History: Petition for review granted by, 02/26/2020
Prior History: [**1] Appeals from the United States Patent and Trademark Office, Patent Trial and Appeal Board in Nos. IPR2015-01096, IPR2015-01102, IPR2015-01103.
Appeal from the United States Patent and Trademark Office, Patent Trial and Appeal Board in No. IPR2015-01092.
Coalition for Affordable Drugs IV v. Celgene Corp., 2016 Pat. App. LEXIS 13407 (Pat. & Trademark Office Bd. App., Oct. 26, 2016)
patents, written decision, reexamination, patients, medium, thalidomide, storage, readable, prior art, motivation, proceedings, drugs, male, prescription, argues, challenges, district court, inter partes, side effect, centralized, teratogenic, registered, pre-AIA, preponderance of evidence, constitutional challenge, ex parte, prescribers, pharmacies, exposure, effects
Patent Law, Jurisdiction & Review, Standards of Review, De Novo Review, Substantial Evidence, Nonobviousness, Claims & Specifications, Claims, Claim Language, Infringement Actions, Claim Interpretation, Elements & Tests, Graham Test, Secondary Considerations, Nonobviousness, Prior Art, Administrative Law, Judicial Review, Reviewability, Preservation for Review, Constitutional Law, Bill of Rights, Fundamental Rights, Eminent Domain & Takings, Ownership, Patents as Property, Business & Corporate Compliance, US Patent & Trademark Office Proceedings, Patent Law, US Patent & Trademark Office Proceedings, Reexamination Proceedings, Defenses, Patent Invalidity, Governments, Legislation, Effect & Operation, Retrospective Operation